Three of four CD4+ TEM≥21% patients assigned to αPD-1 monotherapy instead of αPD-1/αCTLA-4-treatment did not develop hepatitis as predicted; therefore, baseline CD4+ TEM expansion could be taken as a relative contraindication to dual therapy. This evidence concerns the gene CD4 and hepatitis A virus infection.